Silverback Therapeutics

SEATTLE, WA · Founded 2016 · CIK 0001671858 · Biotech · Acquired

ImmunoTAC antibody-TLR agonist conjugate platform for activating immune response against solid tumors

silverbacktx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$139M
7 Form D · Oct 2020
72 months since last filing
Contracts
—
No federal contracts on record
Patents
40
6 granted · 34 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 2 same dayForm D · SEC$200
Private capital raised· 2 of 2 same dayForm D · SEC$10,000,001
Private capital raisedForm D · SEC$25,000
Private capital raisedForm D · SEC$3,749
Private capital raisedForm D · SEC$12,499,994
Private capital raisedForm D · SEC$31,754,277
Private capital raisedForm D · SEC$84,999,995
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2798Immunocore Holdings plc—$140M
2799Black Diamond Therapeutics—$140M
2800VYNE Therapeutics Inc.—$139M
2801Silverback Therapeutics—$139M
2802VANQUA BIO, INC.—$136M
2803Chroma Medicine—$135M
2804ANSA BIOTECHNOLOGIES, INC.—$123M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Vickie CappsDirector
  • Robert HershbergDirector
  • Saqib IslamDirector
  • Scott PlatshonDirector
  • Jonathan RootDirector
  • Thilo SchroederDirector
  • Laura ShawverDirector · Executive Officer
  • Peter ThompsonDirector · Executive Officer

Patents

USPTO · 6 granted of 40
  • ANTI-ASGR1 Antibody Conjugates And Uses Thereofapplication
  • ANTI-ASGR1 Antibody TLR8 Agonist Comprising Conjugates And Uses Thereofgranted
  • Amino-pyrazinecarboxamide Compounds, Conjugates, And Uses Thereofapplication
  • Antibody Conjugates Of Toll-like Receptor Agonistsapplication
  • Anti-mesothelin Antibodies And Immunoconjugates Thereofapplication
  • Cyclic Amino-pyrazinecarboxamide Compounds And Uses Thereofapplication
  • Substituted Benzazepine Compounds, Conjugates, And Uses Thereofapplication
  • NECTIN-4 Antibody Conjugates And Uses Thereofgranted
  • Compositions And Methods For The Treatment Of Viral Infectionsapplication
  • ALK5 Inhibitors, Conjugates, And Uses Thereofapplication
  • ALK5 Inhibitors, Conjugates, And Uses Thereofapplication
  • TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOFapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.